Affimed NV
NASDAQ:AFMD
Affimed NV
NASDAQ:AFMD
Price:
4.35 USD
7.14%
Market Closed
Updated:
Jun 3, 2024
Affimed NV
Revenue
|
Affimed NV
Revenue Peer Comparison
Comparables:
BNTX
MOR
CVAC
IMTX
BIO
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Affimed NV
NASDAQ:AFMD
|
Revenue
€8.3m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
5%
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Revenue
€3.8B
|
CAGR 3-Years
99%
|
CAGR 5-Years
97%
|
CAGR 10-Years
N/A
|
|
|
MorphoSys AG
XETRA:MOR
|
Revenue
€203.5m
|
CAGR 3-Years
18%
|
CAGR 5-Years
18%
|
CAGR 10-Years
10%
|
|
|
CureVac NV
NASDAQ:CVAC
|
Revenue
€53.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Revenue
€54m
|
CAGR 3-Years
20%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Revenue
€899.8m
|
CAGR 3-Years
21%
|
CAGR 5-Years
18%
|
CAGR 10-Years
6%
|
Affimed NV
Revenue Breakdown
Breakdown by Geography
Affimed NV
Affimed NV
|
Total Revenue:
8.3m
EUR
|
|
Usa:
8.3m
EUR
|
|
Germany:
5k
EUR
|
Breakdown by Segments
Affimed NV
Affimed NV
|
Total Revenue:
8.3m
EUR
|
|
Collaboration:
7.8m
EUR
|
|
Service:
510k
EUR
|
See Also
What is Affimed NV's Revenue?
Revenue
8.3m
EUR
8.3m
EUR
Based on the financial report for Dec 31, 2023, Affimed NV's Revenue amounts to 8.3m EUR.
What is Affimed NV's Revenue growth rate?
Revenue CAGR 10Y
5%
5%
Over the last year, the Revenue growth was -80%. The average annual Revenue growth rates for Affimed NV have been -34% over the past three years , -19% over the past five years , and 5% over the past ten years .
You don't have any saved screeners yet
